MTEC member and small business SurgiBox Inc. is an inventor of surgical kits that allow doctors to perform life-saving surgeries anywhere – even in the middle of war zones or other hostile situations.
Inhalon Biopharma, a clinical-stage company advancing a proprietary inhaled antibody platform for treating acute respiratory infections (ARI), today announced that it has been awarded a $5.7 million contract by the U.S Army Medical Research and Development Command (USAMRDC) to support a U.S. Army Military Performance Advancement Initiative (MPAI) project to develop new treatments for COVID-19 and other SARS infections.
The Partial REBOA Outcomes Multicenter Prospective Trial (PROMPT) was selected by the U.S. Army Medical Research and Development Command (USAMRDC) to receive nearly $6 million in funding from the U.S. Department of Defense grant awarded through the Medical Technology Enterprise Consortium (MTEC).
The service’s Medical Research and Development Command awarded the effort’s initial $1.7-million Defense Health Agency contract through the Medical Technology Enterprise Consortium (MTEC) the same year.
The nearly $6 million study is being funded through the U.S. Department of Defense awarded through the Medical Technology Enterprise Consortium.
Astrocyte Pharmaceuticals and the University of Kentucky (partnered with Mitochon Pharmaceuticals) are working diligently to advance the development of drug treatments for repeated mild traumatic brain injury (mTBI). Each received $500,000 awards co-funded by the Medical Technology Enterprise Consortium and BrightFocus Foundation to support preclinical studies, preparation for clinical studies, and submission of an IND application.
The award is part of the Military Prototype Advancement Initiative, funded by the Department of Defense and issued through the Medical Technology Enterprise Consortium, a collaboration of industry and academia to facilitate R&D activities with USAMRDC and other government agencies.
The PROMPT Study will give the trauma community the most compelling data yet on where Partial REBOA using pREBOA-PRO will fit in their toolkit to improve patient outcomes and save lives.
Vivacelle Bio, Inc., a privately held life science company focused on the development of treatments for hypovolemia in shock including septic shock and hemorrhagic shock, announced the successful completion of its Phase IIa clinical trial of VBI-S in septic shock patients with severe hypovolemia.
Advanced Technology International (ATI) and TechConnect today announced 25 finalists who will pitch on September 28, 2022 at Defense TechConnect Innovation Summit for $200,000 in non-dilutive awards. These candidates receive membership from four consortia with a combined $50B in federal contracting authority including: Medical CBRN Defense Consortium (MCDC), Countering Weapons of Mass Destruction Consortium (CWMD), Medical Technology Enterprise Consortium (MTEC), and Senior Healthcare Innovation Consortium (SHIC).
